ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 3, 2017 to discuss its third quarter 2017 financial results. Management also will provide a brief update on the business.

To access the live call by phone, dial 719-325-4907; the conference ID is 6498153. The call also may be accessed through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through November 17, 2017.

About ImmunoGen, Inc.ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyla®, and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

For InvestorsImmunoGen, Inc.Sarah Kiely, 781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen, Inc.Courtney O'Konek, 781-895-0600courtney.okonek@immunogen.comorFTI Consulting, Inc.Robert Stanislaro, 212-850-5657robert.stanislaro@fticonsulting.com

ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more ImmunoGen Charts.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more ImmunoGen Charts.